Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

4.13
-0.0100-0.24%
Post-market: 4.160.0292+0.71%18:37 EDT
Volume:889.03K
Turnover:3.65M
Market Cap:129.23M
PE:-1
High:4.28
Open:4.23
Low:4.01
Close:4.14
52wk High:50.40
52wk Low:4.01
Shares:31.29M
Float Shares:18.39M
Volume Ratio:1.15
T/O Rate:4.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1300
EPS(LYR):-2.8503
ROE:-59.21%
ROA:-37.36%
PB:0.59
PE(LYR):-1.45

Loading ...

Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

GlobeNewswire
·
Sep 03

Quince Therapeutics to Participate in September 2026 Investor Conferences

GlobeNewswire
·
Sep 03

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Sep 03

Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference

GlobeNewswire
·
Sep 03

HC Wainwright Initiate Neurosense Therapeutics at Buy With $8 Price Target

MT Newswires Live
·
Sep 03

NeuroSense Therapeutics Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
Sep 03

TScan Therapeutics Cut to Hold from Buy by Needham

Dow Jones
·
Sep 03

Onconic Therapeutics Independent Director Resigns After Public Appointment

TIPRANKS
·
Sep 03

Cutia Therapeutics' Marketing Application for Botox Product Accepted in China

MT Newswires Live
·
Sep 03

IMPACT Therapeutics CEO Boosts Stake in Hong Kong–Listed Biopharma Group

TIPRANKS
·
Sep 03

Alterity Therapeutics to Spotlight MSA Program at Cantor Global Healthcare Conference

TIPRANKS
·
Sep 03

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Sep 03

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Sep 03

Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewswire
·
Sep 03

Needham Downgrades TScan Therapeutics to Hold From Buy

MT Newswires Live
·
Sep 03

TScan Therapeutics downgraded to Hold from Buy at Needham

TIPRANKS
·
Sep 03

Halozyme Therapeutics Price Target Maintained with a $115.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 03

Wedbush Downgrades TScan Therapeutics to Neutral From Outperform, Adjusts Price Target to $1 From $5

MT Newswires Live
·
Sep 02

Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker

GlobeNewswire
·
Sep 02

Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference

GlobeNewswire
·
Sep 02